Pharma

Your Article Summary

See Latest Articles

Fda advisory panel makes favorable recommendation for glaxosmithkline and genmab's arzerra (ofatumumab)
Genmab, 06/01/09

GlaxoSmithKline and Genmab A/S announced that the United States Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10 to 3 that the ARZERRA data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09

Safety concerns slow new drug review and approval processes
Formulary , 12/02/09

Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09

 See all of Drug/Product Approvals